Tumour neoantigen mimicry by microbial species in cancer immunotherapy

Area of Science:

• Oncology
• Immunology
• Microbiology

Background:

• Tumor neoantigens, derived from cancer-specific mutations, offer a unique molecular signature for cancer detection and targeted therapy.
• Immune checkpoint blockade (ICB) therapy leverages the immune system's ability to recognize and attack cancer cells via these neoantigens.
• The gut microbiome and other microbial communities can produce epitopes that mimic tumor neoantigens.

Purpose of the Study:

• To highlight the critical role of tumor neoantigens in effective cancer immunotherapy.
• To explore the influence of microbiome-mediated tumor neoantigen mimicry on the outcomes of ICB therapy.
• To discuss the implications of neoantigen mimicry for personalized cancer treatment strategies.

Main Methods:

• Review of current literature on tumor neoantigens and cancer immunotherapy.
• Analysis of mechanisms by which microbial epitopes can resemble tumor neoantigens.
• Discussion of the impact of microbiome composition on anti-cancer immune responses.

Main Results:

• Tumor neoantigens are essential for eliciting a specific anti-cancer immune response.
• Microbial mimicry of tumor neoantigens can modulate the host's immune response to cancer.
• Variability in microbiome composition may explain differential patient responses to ICB therapy.

Conclusions:

• Tumor neoantigens are fundamental for successful cancer immunotherapy.
• Microbiome-mediated neoantigen mimicry is an emerging factor influencing the efficacy of ICB.
• Understanding neoantigen mimicry is crucial for advancing future cancer immunotherapy approaches.